Atara Biotherapeutics Inc. (ATRA) CEO Sells $220,080.00 in Stock
Atara Biotherapeutics Inc. (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 23rd. The stock was sold at an average price of $18.34, for a total value of $220,080.00. Following the sale, the chief executive officer now directly owns 555,044 shares of the company’s stock, valued at $10,179,506.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Atara Biotherapeutics Inc. (NASDAQ:ATRA) traded up 6.28% during trading on Wednesday, reaching $19.45. The company had a trading volume of 196,158 shares. The firm’s market capitalization is $561.33 million. The firm’s 50 day moving average price is $16.69 and its 200 day moving average price is $19.65. Atara Biotherapeutics Inc. has a 12-month low of $12.45 and a 12-month high of $40.80.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Friday, November 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by $0.10. Equities research analysts forecast that Atara Biotherapeutics Inc. will post ($3.05) EPS for the current year.
A number of brokerages have commented on ATRA. Canaccord Genuity set a $47.00 price objective on Atara Biotherapeutics and gave the stock a “buy” rating in a report on Sunday, November 6th. Zacks Investment Research lowered Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 26th. Jefferies Group began coverage on Atara Biotherapeutics in a report on Monday, October 24th. They set a “buy” rating and a $23.00 price objective for the company. Goldman Sachs Group Inc. lowered Atara Biotherapeutics from a “neutral” rating to a “sell” rating and decreased their price objective for the stock from $23.00 to $16.00 in a report on Thursday, September 15th. Finally, Citigroup Inc. upped their target price on Atara Biotherapeutics from $8.00 to $10.00 and gave the company a “sell” rating in a report on Friday, August 19th. Three analysts have rated the stock with a sell rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $25.86.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC boosted its stake in shares of Atara Biotherapeutics by 2,266.0% in the second quarter. Barclays PLC now owns 4,803 shares of the company’s stock valued at $108,000 after buying an additional 4,600 shares during the last quarter. Panagora Asset Management Inc. bought a new stake in shares of Atara Biotherapeutics during the third quarter valued at approximately $110,000. BlackRock Group LTD boosted its stake in shares of Atara Biotherapeutics by 3.7% in the third quarter. BlackRock Group LTD now owns 5,532 shares of the company’s stock valued at $119,000 after buying an additional 198 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Atara Biotherapeutics by 464.3% in the second quarter. BlackRock Inc. now owns 6,100 shares of the company’s stock valued at $137,000 after buying an additional 5,019 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in shares of Atara Biotherapeutics by 6,736.5% in the second quarter. PNC Financial Services Group Inc. now owns 6,563 shares of the company’s stock valued at $148,000 after buying an additional 6,467 shares during the last quarter. Institutional investors own 74.45% of the company’s stock.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.